Gossamer Bio vs Tenax Therapeutics
GOSS and TENX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GOSS and TENX compare
Gossamer Bio and Tenax Therapeutics are about the same size, with market caps of $67.1M and $60.6M.
Tenax Therapeutics scores higher on the StockData Score (6 against 2 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GOSS | TENX |
|---|---|---|
| Size and price | ||
| Market cap | $67.1M | $60.6M |
| Share price | $10.97 | $1.62 |
| Change, 1 year | −94.9% | −76.8% |
| Change, 5 years | −98.8% | −99.9% |
| Beta (5Y) | 1.58 | 0.62 |
| Employees | 161 | 14 |
| StockData Score | ||
| Total score | 2 | 6 (better) |
| Valuation score | 1 | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.9× | – |
| P/B | – | 0.6× |
| FCF yield | −233% | – |
| Growth | ||
| Revenue growth (TTM) | 78.0% | – |
| Profitability | ||
| Operating margin | −140% | – |
| Net margin | −159% | – |
| FCF margin | −199% | – |
| Return on equity | – | −64.2% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −10.3× | – |
| Current ratio | 0.60 | 14.01 (better) |
| Altman Z-score | −37.94 | −1.49 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 78.0% | 81.1% |
| Held by insiders | – | 4.8% |
| Insider net buying, 12 months | – | $6.5M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 16.3% |
Go deeper
- GOSS stock overview
- GOSS income statement
- GOSS valuation and score
- TENX stock overview
- TENX income statement
- TENX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.